Systemic treatment of non-small cell lung cancer in the metastatic stage. Quo vadis

作者：Reinmuth N^*; Tufman A; Steins M; Reck M

来源：Onkologe, 2014, 20(10): 943-+.

DOI：10.1007/s00761-014-2678-2

• NSCLC
• EGFR
• Immune therapy
• Angiogenesis
• Biomarkers

Background. The majority of patients with non-small cell lung cancer (NSCLC) will receive systemic therapy for treatment of their disease.
Objective. Current developments for systemic therapy of patients with metastatic non-small cell lung cancer are summmarised.
Materials and methods. Description, analysis and discussion of recent clinical studies with consideration of national and international treatment guidelines.
Results. In contrast to the 1990s, the treatment options for systemic therapy have considerably evolved including new anti-neoplastic drugs, agents targeting specific molecular alterations and new treatment modalities such as maintenance therapy and immunotherapy. Consequently, preselection of patients by defined clinical, histological and molecular parameters now has a central role for planning diagnostic procedures and assessing therapeutic strategies.
Conclusion. For every patient, the applicable profile of molecular alterations should be assessed. Appropriate therapeutic options need to be individually duscussed.

• 出版日期2014-10